Blog
Feedback
schliessen

Filtern

 

Bibliotheken

Logo der Bibliothek

Logo FID Pharmazie PubPharm Discovery System Universitätsbibliothek Braunschweig Institut für Informationssysteme

Cellular Senescence-Inducing Small Molecules for Cancer Treatment

Recently, the chemotherapeutic drug-induced cellular senescence has been considered a promising anti-cancer approach. The drug-induced senescence, which shows both similar and different hallmarks from replicative and oncogene-induced senescence, was regarded as a key determinant of tumor response to chemotherapy in vitro and in vivo. To date, an amount of effective chemotherapeutic drugs that can evoke senescence in cancer cells have been reported. The targets of these drugs differ substantially, including senescence signaling pathways, DNA replication process, DNA damage pathways, epigenetic modifications, microtubule polymerization, senescence-associated secretory phenotype (SASP), and so on. By summarizing senescence-inducing small molecule drugs together with their specific traits and corresponding mechanisms, this review is devoted to inform scientists to develop novel therapeutic strategies against cancer through inducing senescence

Year of Publication: 2019
Contained in: Current cancer drug targets Vol. 19, No. 2 (2019), p. 109-119
All journal articles: Search for all articles in this journal
Language: English
Contributors: Liu, Peng | Author
Lu, Ziwen
Wu, Yanfang
Shang, Dongsheng
Zhao, Zhicong
Shen, Yanting
Zhang, Yafei
Zhu, Feifei
Liu, Hanqing
Tu, Zhigang
Full text access:
Electronic availability is being checked...
Links: Full Text (dx.doi.org)
Keywords: Cancer
DNA damage responses
Journal Article
Research Support, Non-U.S. Gov't
SASP
senescence-related signaling pathways
senescence
small molecule drugs.
ISSN: 1873-5576
Note: Copyright: From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Notes: Date Revised 27.01.2020
published: Print
Citation Status In-Process
Copyright: From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Physical Description: Online-Ressource
ID (e.g. DOI, URN): 10.2174/1568009618666180530092825
more publication details ...

Associated Publications

  • Associated records are being queried...
more (+)
Internes Format
LEADER 03023nma a2200637 c 4500
001 NLM285269267
003 DE-601
005 20200220225705.0
007 cr uuu---uuuuu
008 180604s2019 000 0 eng d
024 7 |a 10.2174/1568009618666180530092825  |2 doi 
028 5 2 |a pubmed20n1065.xml 
035 |a (DE-599)NLM29848278 
040 |b ger  |c GBVCP 
041 0 |a eng 
100 1 |a Liu, Peng 
245 1 0 |a Cellular Senescence-Inducing Small Molecules for Cancer Treatment  |h Elektronische Ressource 
300 |a Online-Ressource 
500 |a Date Revised 27.01.2020 
500 |a published: Print 
500 |a Citation Status In-Process 
500 |a Copyright: From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine 
520 |a Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net. 
520 |a Recently, the chemotherapeutic drug-induced cellular senescence has been considered a promising anti-cancer approach. The drug-induced senescence, which shows both similar and different hallmarks from replicative and oncogene-induced senescence, was regarded as a key determinant of tumor response to chemotherapy in vitro and in vivo. To date, an amount of effective chemotherapeutic drugs that can evoke senescence in cancer cells have been reported. The targets of these drugs differ substantially, including senescence signaling pathways, DNA replication process, DNA damage pathways, epigenetic modifications, microtubule polymerization, senescence-associated secretory phenotype (SASP), and so on. By summarizing senescence-inducing small molecule drugs together with their specific traits and corresponding mechanisms, this review is devoted to inform scientists to develop novel therapeutic strategies against cancer through inducing senescence 
611 2 7 |a Journal Article  |2 gnd 
611 2 7 |a Research Support, Non-U.S. Gov't  |2 gnd 
655 7 |a Cancer  |2 gnd 
655 7 |a DNA damage responses  |2 gnd 
655 7 |a SASP  |2 gnd 
655 7 |a senescence  |2 gnd 
655 7 |a senescence-related signaling pathways  |2 gnd 
655 7 |a small molecule drugs.  |2 gnd 
689 0 0 |A f  |a Journal Article 
689 0 1 |A f  |a Research Support, Non-U.S. Gov't 
689 0 |5 DE-601 
689 1 0 |a Cancer 
689 1 1 |a DNA damage responses 
689 1 2 |a SASP 
689 1 3 |a senescence 
689 1 4 |a senescence-related signaling pathways 
689 1 5 |a small molecule drugs. 
689 1 |5 DE-601 
700 1 |a Lu, Ziwen 
700 1 |a Wu, Yanfang 
700 1 |a Shang, Dongsheng 
700 1 |a Zhao, Zhicong 
700 1 |a Shen, Yanting 
700 1 |a Zhang, Yafei 
700 1 |a Zhu, Feifei 
700 1 |a Liu, Hanqing 
700 1 |a Tu, Zhigang 
773 0 8 |i in  |t Current cancer drug targets  |g Vol. 19, No. 2 (2019), p. 109-119  |q 19:2<109-119  |w (DE-601)NLM120493810  |x 1873-5576 
856 4 1 |u http://dx.doi.org/10.2174/1568009618666180530092825  |3 Volltext 
912 |a GBV_NLM 
951 |a AR 
952 |d 19  |j 2019  |e 2  |h 109-119